Juris Hmelnickis PhD, Chairman of the Board of JSC Kalceks, explains the story and the evolution of the company in Latvia, its key products in the CNS therapeutic area and how they were able to piggyback on the established footprint of their mother company, JSC Grindeks, to launch products in many different regulatory requirements across Europe.
Can you give us a sense of Kalceks, the scope of its operations and what it is offering today?
"As a small country, I believe it is much more lucrative to focus on exports and on attracting foreign investment rather than merely focusing on the local market and on protecting local businesses."
